Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC105 in Acute Traumatic Spinal Cord Injury
NCT01750684Phase 2Terminated
- Sponsor
- Acorda Therapeutics
- Start
- Jul 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of AC105 in spinal cord injury (SCI), sponsored by Acorda Therapeutics. Started Jul 2013; status: terminated.
02
Drugs
AC105
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT01750684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01750684.